Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000025538
Ethics application status
Approved
Date submitted
16/11/2023
Date registered
12/01/2024
Date last updated
12/01/2024
Date data sharing statement initially provided
12/01/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
A study to assess two formulations of VLS-01 (VLS-01-IV and VLS-01-BU) in Healthy Adult Volunteers
Query!
Scientific title
A Phase 1b, Single-Centre, Open-Label Dose Ranging Study of an Optimized Formulation of VLS-01 in Healthy Adult Volunteers
Query!
Secondary ID [1]
310613
0
VLS-01-102
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Depression
331493
0
Query!
Condition category
Condition code
Mental Health
328229
328229
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The participants will receive a total of 4 administrations of VLS-01 administered via IV (VLS-01 IV) in treatment period 1 and via buccal administration (VLS-01-BU) in treatment period 2 .
Dose:
VLS-01-IV: Single dose of 30 mg is a 57 minute IV infusion which will be administered by a registered nurse and monitored on site.
VLS-01-BU: Single doses of either 240mg or 160 mg, and 60 mg, and 20 mg with option to modify dose.. This is administered approximately 28 days after completion of treatment period 1..
Duration of administration; single day – until dissolved and monitored on site.
Dosage based on Phase 1a study. The Safety Monitoring Group (SMG) will review safety, tolerability, PK, and PD results, where available, after the last participant completes each of the first two doses of VLS-01-BU. The moderate and low doses may be modified by the SMG based on observed PK and PD to ensure that the three doses of VLS-01-BU produce a sufficient range of PK and PD effects
Dosing is performed on site under supervision of site staff.
Query!
Intervention code [1]
327018
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
336094
0
Assess the plasma PK of VLS-01-IV (IV infusion) and multiple doses of VLS-01-BU (buccal) and its 2 predominant metabolites (DMT-NO and IAA) .
Query!
Assessment method [1]
336094
0
Plasma PK parameters of VLS-01-IV and VLS-01-BU and its 2 predominant metabolites, DMT-NO and IAA.
PK parameters: AUC, Cmax, Tmax, Lambda z or kel, t1/2, CL or CL/F, Vz/F or Vz, Ae, Fe, CLr
Query!
Timepoint [1]
336094
0
Predose (within 2 h of dose) and 5, 10, 20, 30, 40, 50, 60, 90 (each ± 2 minutes), 120, 150, 180, 240, 360, and 480 minutes (each ± 10 minutes) after the start of treatment.
Query!
Primary outcome [2]
336853
0
Assess the urine PK of VLS-01-IV (IV infusion) and multiple doses of VLS-01-BU (buccal) and its 2 predominant metabolites (DMT-NO and IAA) .
Query!
Assessment method [2]
336853
0
Urine PK parameters of VLS-01-IV and VLS-01-BU and its 2 predominant metabolites, DMT-NO and IAA.
PK parameters: AUC, Cmax, Tmax, Lambda z or kel, t1/2, CL or CL/F, Vz/F or Vz, Ae, Fe, CLr
Query!
Timepoint [2]
336853
0
Predose (within 2 hours before VLS-01 administration) and within 0 to 4 and 4 to 8 hours (both ± 30 minutes) after the start of treatment.
Query!
Secondary outcome [1]
427836
0
To assess the safety and tolerability of VLS-01 when administered as a single-dose of VLS-01-IV and multiple doses of VLS-01-BU in healthy adult participants.
Assessed as a composite secondary outcome.
Query!
Assessment method [1]
427836
0
Incidence and severity of treatment-emergent adverse events (TEAEs) will be assessed for severity and causality (relationship of event to the investigational product) by the study investigator
Changes in clinical laboratory parameters
Change in vital signs measurements. Vital signs include measurement of heart rate (HR) respiration rate (RR), systolic and diastolic blood pressure (BP) and body temperature.
Changes in the electrocardiogram (ECG) findings)
Suicidal ideation will be measured by Columbia suicide severity rating scale (C-SSRS) score
.
Query!
Timepoint [1]
427836
0
Adverse events assessed from baseline until End of study visit (EOS)
Clinical labs at Screening, Predose and 6 hours post dose on Day 1, safety follow up and at End of study
Oral examination is done at Screening and on IP administration days.
Vital signs collected at Predose (within 2 h of dose) and 0.25, 0.5, 0.75, 1 h (plus or minus 5 minutes), 1.5, 2, 3, 4, and 6 h (plus or minus 15 minutes) post dose
ECG done at Predose, 4 hour and 6 hours post dose
C-SSRS administered at Screening, predose and 6h post dose on IP administration days, Safety follow up, and End of study (EoS)
Query!
Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if all the following criteria apply:
1. Participant must be 18 to 65 years of age (inclusive) at the time of signing the informed consent.
2. Participants who are overtly healthy as determined by medical history, physical examination, vital sign measurements, electrocardiogram (ECG), and laboratory safety tests performed at the Screening Visit and or before the first dose of IMP.
3. Participants who are not lactating or pregnant as confirmed by a serum pregnancy test at Screening and negative urine pregnancy test before dosing (applies only to participants of childbearing potential [POCBP]).
4 Body weight no greater than 100 kg and body mass index (BMI) within the range 20-32 kg per m2 (inclusive) at Screening.
5.Participant agrees to comply with using a double barrier method of contraception or sexual abstinence and not donate sperm or ova.
6. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
7. Smoke no more than 8 cigarettes, pipes, cigars, e-cigarettes or equivalent per month, including nicotine products, from 3 months prior to Screening and is willing to abstain from smoking/using nicotine products for 24 hours before VLS-01 administration and
during the entire dosing Visit.
8. Agrees to be available for all study Visits and cooperates fully with the requirements of the study protocol, including the Schedule of Assessments.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
1. Current or past history schizophrenia or other psychotic disorders, or bipolar I or II disorder, has a past or current history of a significant mental, behavioral, or neurodevelopmental disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition including, but not limited to, diagnoses of: organic, including symptomatic, mental disorders; mental and behavioral disorders due to psychoactive substance use; schizophrenia, schizotypal, and delusional disorders; mood (affective) disorders (only current diagnosis exclusionary); neurotic, stress-related and somatoform disorders; or disorders of adult personality and behavior.
2. Has a mild, moderate, or severe substance use disorder (drug or alcohol) within the 6 months before Screening and/or history of moderate or severe substance use disorder (drug or alcohol) within the previous 5 years before Screening.
3. Has homicidal ideation or intent per the investigator’s clinical judgment.
4. Risk of suicide as determined by Columbia Suicide Severity Scale (C-SSRS).
5. Has a history of clinically significant cardiovascular, cerebrovascular, or peripheral vascular disease, including but not limited to unstable angina, myocardial infarction, congestive heart failure, cardiac arrhythmia, hypertension, hypotension, bradycardia, or tachycardia.
6. History of seizures, convulsions or increased intra-cranial pressure except for pediatric febrile seizures.
7. Has an active malignancy, or history of malignancy, excluding basal or squamous cell carcinoma of the skin, within 2 years before Screening.
8. History of risk factors including hypokalemia or a family history of Long QT Syndrome.
9. Has clinically relevant long-term coronavirus disease-2019 (COVID-19) symptoms or current signs or symptoms of COVID-19.
10. Has a biological 1st degree relative with schizophrenia, bipolar I/II, and/or psychotic disorder (unless induced by substance or medical condition).
11. Has a history of greater than 25 lifetime administrations of psychedelic drugs, and/or last use of a psychedelic drug within 6 months before Screening and/or has reported HPPD or other significant AEs after prior use of hallucinogens
12. Is unable or unwilling to refrain from using any recreational psychoactive drugs (other than tobacco and nicotine products), including alcohol, from 24 hours before the start of IMP infusion until 24 hours after dosing has been completed on dosing days.
13. Is unable or unwilling to refrain from using tobacco and nicotine products for 24 hours before the start of IMP administration until the end of the dosing Visit on each dosing day.
14. Has donated blood or plasma within 30 days before Screening, lost more than 500 mL of whole blood within the 30 days before Screening, or received a blood transfusion within 1 year before Screening
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Pharmacokinetics / pharmacodynamics
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/02/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
26/02/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
4/06/2024
Query!
Actual
Query!
Sample size
Target
16
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
25773
0
New Zealand
Query!
State/province [1]
25773
0
Auckland
Query!
Funding & Sponsors
Funding source category [1]
314826
0
Commercial sector/Industry
Query!
Name [1]
314826
0
atai Therapeutics Pty. Ltd.
Query!
Address [1]
314826
0
330 Collins Street Melbourne Victoria 3000 Australia
Query!
Country [1]
314826
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
atai Therapeutics Pty. Ltd.
Query!
Address
330 Collins Street Melbourne Victoria 3000 Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
316818
0
None
Query!
Name [1]
316818
0
Query!
Address [1]
316818
0
Query!
Country [1]
316818
0
Query!
Other collaborator category [1]
282813
0
Commercial sector/Industry
Query!
Name [1]
282813
0
Novotech (New Zealand) Limited
Query!
Address [1]
282813
0
Level 6, 2-6 Crowhurst Street, Newmarket, Auckland, 1023, New Zealand
Query!
Country [1]
282813
0
New Zealand
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
313832
0
Central Health and Disability Ethics Committees
Query!
Ethics committee address [1]
313832
0
Ministry of Health, 133 Molesworth Street PO Box 5013, Wellington 6011, New Zealand
Query!
Ethics committee country [1]
313832
0
New Zealand
Query!
Date submitted for ethics approval [1]
313832
0
12/09/2023
Query!
Approval date [1]
313832
0
15/12/2023
Query!
Ethics approval number [1]
313832
0
Query!
Summary
Brief summary
Depression and anxiety are common mental health disorders that result in individual suffering and have a significant socio-economic impact. In New Zealand, approximately 1 in 7 people will experience depression during their lifetime. Traditional antidepressants often take weeks to months to positively affect mood but are ineffective in approximately 30% of all patients, which often leads to treatment resistant
depression (TRD). Treatment of TRD is difficult and may include different pharmacological treatments, or brain stimulation therapies (which are often accompanied by intolerable side effects). However, no single treatment is effective for all TRD patients and there is a significant medical need for effective TRD therapies that are fast-acting and less invasive.
As such, there is an urgent need to improve and expand therapeutic options for these TRD patients. This study will provide critical data and will inform the ongoing development of VLS-01 in the treatment of TRD.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
129486
0
Dr Christian Schwabe
Query!
Address
129486
0
Auckland Clinical Studies (ACS) 3 Ferncroft Street, Grafton, Auckland, 1010 New Zealand
Query!
Country
129486
0
New Zealand
Query!
Phone
129486
0
+64 93733474
Query!
Fax
129486
0
Query!
Email
129486
0
[email protected]
Query!
Contact person for public queries
Name
129487
0
Dr Christian Schwabe
Query!
Address
129487
0
Auckland Clinical Studies (ACS) 3 Ferncroft Street, Grafton, Auckland, 1010 New Zealand
Query!
Country
129487
0
New Zealand
Query!
Phone
129487
0
+64 93733474
Query!
Fax
129487
0
Query!
Email
129487
0
[email protected]
Query!
Contact person for scientific queries
Name
129488
0
Dr Christian Schwabe
Query!
Address
129488
0
Auckland Clinical Studies (ACS) 3 Ferncroft Street, Grafton, Auckland, 1010 New Zealand
Query!
Country
129488
0
New Zealand
Query!
Phone
129488
0
+64 93733474
Query!
Fax
129488
0
Query!
Email
129488
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
No other documents available
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF